Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia
IntroductionCasirivimab and imdevimab (CAS/IMV) are two non-competing, high-affinity human IgG1 anti-SARS-CoV-2 monoclonal antibodies, that showed a survival benefit in seronegative hospitalized patients with COVID-19. This study aimed to estimate the day-28 risk of mechanical ventilation (MV) and death in individuals hospitalized for severe COVID-19 pneumonia and receiving CAS/IMV. Additionally, it aimed to identify variables measured at the time of hospital admission that could predict these outcomes and derive a prediction algorithm.MethodsThis is a retrospective, observational cohort study conducted in 12 hospitals in Italy. Adult patients who were consecutively hospitalized from November 2021 to February 2022 receiving CAS/IMV were included. A multivariable logistic regression model was used to identify predictors of MV or death by day 28 from treatment initiation, and β-coefficients from the model were used to develop a risk score that was derived by means of leave-one-out internal cross-validation (CV), external CV, and calibration. Secondary outcome was mortality.ResultsA total of 480 hospitalized patients in the training set and 157 patients in the test set were included. By day 28, 36 participants (8%) underwent MV and 28 died (6%) for a total of 58 participants (12%) experiencing the composite primary endpoint. In multivariable analysis, four factors [age, PaO2/FiO2 ratio, lactate dehydrogenase (LDH), and platelets] were independently associated with the risk of MV/death and were used to generate the proposed risk score. The accuracy of the score in the area under the curve (AUC) was 0.80 and 0.77 in internal validation and test for the composite endpoint and 0.87 and 0.86 for death, respectively. The model also appeared to be well calibrated with the raw data.ConclusionThe mortality risk reported in our study was lower than that previously reported. Although CAS/IMV is no longer used, our score might help in identifying which patients are not likely to benefit from monoclonal antibodies and may require alternative interventions..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in Medicine - 11(2024) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alessandro Cozzi-Lepri [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.3389/fmed.2024.1293431 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ09229524X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ09229524X | ||
| 003 | DE-627 | ||
| 005 | 20240412121113.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2024.1293431 |2 doi | |
| 035 | |a (DE-627)DOAJ09229524X | ||
| 035 | |a (DE-599)DOAJ0b97388ee1594886bbcecb9b15b4c631 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Alessandro Cozzi-Lepri |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a IntroductionCasirivimab and imdevimab (CAS/IMV) are two non-competing, high-affinity human IgG1 anti-SARS-CoV-2 monoclonal antibodies, that showed a survival benefit in seronegative hospitalized patients with COVID-19. This study aimed to estimate the day-28 risk of mechanical ventilation (MV) and death in individuals hospitalized for severe COVID-19 pneumonia and receiving CAS/IMV. Additionally, it aimed to identify variables measured at the time of hospital admission that could predict these outcomes and derive a prediction algorithm.MethodsThis is a retrospective, observational cohort study conducted in 12 hospitals in Italy. Adult patients who were consecutively hospitalized from November 2021 to February 2022 receiving CAS/IMV were included. A multivariable logistic regression model was used to identify predictors of MV or death by day 28 from treatment initiation, and β-coefficients from the model were used to develop a risk score that was derived by means of leave-one-out internal cross-validation (CV), external CV, and calibration. Secondary outcome was mortality.ResultsA total of 480 hospitalized patients in the training set and 157 patients in the test set were included. By day 28, 36 participants (8%) underwent MV and 28 died (6%) for a total of 58 participants (12%) experiencing the composite primary endpoint. In multivariable analysis, four factors [age, PaO2/FiO2 ratio, lactate dehydrogenase (LDH), and platelets] were independently associated with the risk of MV/death and were used to generate the proposed risk score. The accuracy of the score in the area under the curve (AUC) was 0.80 and 0.77 in internal validation and test for the composite endpoint and 0.87 and 0.86 for death, respectively. The model also appeared to be well calibrated with the raw data.ConclusionThe mortality risk reported in our study was lower than that previously reported. Although CAS/IMV is no longer used, our score might help in identifying which patients are not likely to benefit from monoclonal antibodies and may require alternative interventions. | ||
| 650 | 4 | |a casirivimab/imdevimab | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a mechanical ventilation | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a prediction score | |
| 650 | 4 | |a SARS-CoV-2 | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Vanni Borghi |e verfasserin |4 aut | |
| 700 | 0 | |a Salvatore Rotundo |e verfasserin |4 aut | |
| 700 | 0 | |a Bianca Mariani |e verfasserin |4 aut | |
| 700 | 0 | |a Anna Ferrari |e verfasserin |4 aut | |
| 700 | 0 | |a Cosmo Del Borgo |e verfasserin |4 aut | |
| 700 | 0 | |a Francesca Bai |e verfasserin |4 aut | |
| 700 | 0 | |a Pietro Colletti |e verfasserin |4 aut | |
| 700 | 0 | |a Piermauro Miraglia |e verfasserin |4 aut | |
| 700 | 0 | |a Carlo Torti |e verfasserin |4 aut | |
| 700 | 0 | |a Anna Maria Cattelan |e verfasserin |4 aut | |
| 700 | 0 | |a Giovanni Cenderello |e verfasserin |4 aut | |
| 700 | 0 | |a Marco Berruti |e verfasserin |4 aut | |
| 700 | 0 | |a Carlo Tascini |e verfasserin |4 aut | |
| 700 | 0 | |a Giustino Parruti |e verfasserin |4 aut | |
| 700 | 0 | |a Simona Coladonato |e verfasserin |4 aut | |
| 700 | 0 | |a Andrea Gori |e verfasserin |4 aut | |
| 700 | 0 | |a Giulia Marchetti |e verfasserin |4 aut | |
| 700 | 0 | |a Miriam Lichtner |e verfasserin |4 aut | |
| 700 | 0 | |a Luigi Coppola |e verfasserin |4 aut | |
| 700 | 0 | |a Chiara Sorace |e verfasserin |4 aut | |
| 700 | 0 | |a Alessandra D'Abramo |e verfasserin |4 aut | |
| 700 | 0 | |a Valentina Mazzotta |e verfasserin |4 aut | |
| 700 | 0 | |a Giovanni Guaraldi |e verfasserin |4 aut | |
| 700 | 0 | |a Erica Franceschini |e verfasserin |4 aut | |
| 700 | 0 | |a Marianna Meschiari |e verfasserin |4 aut | |
| 700 | 0 | |a Loredana Sarmati |e verfasserin |4 aut | |
| 700 | 0 | |a Andrea Antinori |e verfasserin |4 aut | |
| 700 | 0 | |a Emanuele Nicastri |e verfasserin |4 aut | |
| 700 | 0 | |a Cristina Mussini |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Medicine |d Frontiers Media S.A., 2014 |g 11(2024) |w (DE-627)DOAJ000022292 |x 2296858X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fmed.2024.1293431 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/0b97388ee1594886bbcecb9b15b4c631 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fmed.2024.1293431/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2296-858X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 | ||